Literature DB >> 19242341

Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit.

Andrew F Shorr1.   

Abstract

OBJECTIVE: To review studies addressing mortality, length of stay (LOS), and cost of resistant Gram-negative bacterial infections in the intensive care unit (ICU). DATA SOURCES AND STUDY SELECTION: A qualitative review of published studies identified through PubMed search was performed. Study exclusion criteria were population <40 adults or <39% of cases in the ICU. Criteria for judging study quality were prospective analysis, multicenter study, author-specified diagnostic criteria, appropriate control group defined as patients with infections caused by susceptible bacteria, adjustments for confounding factors, and use of cost. DATA EXTRACTION AND SYNTHESIS: Twenty-one original studies and a meta-analysis, which included three of the original studies, were identified. Infections caused by mixed resistant Gram-negative bacteria, extended-spectrum beta-lactamase-producing Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa, and Acinetobacter species were generally associated with increased mortality and LOS, especially in univariate analyses. Economic analyses performed in eight studies indicated that these resistant Gram-negative infections were also associated with increased patient charges or hospital costs. Associations sometimes disappeared in multivariate analyses after adjusting for variables significant in univariate analyses.
CONCLUSION: The collective findings of the studies in this review suggested that Gram-negative bacterial resistance increases the burden in the ICU as measured by mortality, LOS, and charges. More prospective studies are needed to explore methods for combating Gram-negative resistance, including prevention, education, and better antimicrobial therapy. For example, well-designed research is needed to determine the cost-effectiveness of appropriate empiric therapy with broad-spectrum agents active against resistant Gram-negative bacteria followed by de-escalation.

Entities:  

Mesh:

Year:  2009        PMID: 19242341     DOI: 10.1097/CCM.0b013e31819ced02

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  49 in total

Review 1.  Preventing the spread of multidrug-resistant gram-negative pathogens: recommendations of an expert panel of the German Society For Hygiene and Microbiology.

Authors:  Frauke Mattner; Franz-C Bange; Elisabeth Meyer; Harald Seifert; Thomas A Wichelhaus; Iris F Chaberny
Journal:  Dtsch Arztebl Int       Date:  2012-01-20       Impact factor: 5.594

Review 2.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

3.  After standard dosage of piperacillin plasma concentrations of drug are subtherapeutic in burn patients.

Authors:  Katharina Olbrisch; Tobias Kisch; Julia Thern; Evelyn Kramme; Jan Rupp; Tobias Graf; Sebastian G Wicha; Peter Mailänder; Walter Raasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-27       Impact factor: 3.000

4.  Infections caused by multidrug resistant organisms are not associated with overall, all-cause mortality in the surgical intensive care unit: the 20,000 foot view.

Authors:  Laura H Rosenberger; Damien J LaPar; Robert G Sawyer
Journal:  J Am Coll Surg       Date:  2012-03-13       Impact factor: 6.113

5.  Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Maya Hites; Marjorie Beumier; Sabino Scolletta; Frédérique Jacobs
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

6.  Single-Center Pharmacokinetic Study and Simulation of a Low Meropenem Concentration in Brain-Dead Organ Donors.

Authors:  Jae-Myeong Lee; Joo Won Lee; Tae Seok Jeong; Eun Sook Bang; So Hee Kim
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

7.  Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

8.  Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.

Authors:  Alexandro Rodríguez-Rojas; María D Maciá; Alejandro Couce; Cristina Gómez; Alfredo Castañeda-García; Antonio Oliver; Jesús Blázquez
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

9.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Thierry Dugernier; Herbert Spapen; Isabelle Delattre; Xavier Wittebole; Daniel De Backer; Brice Layeux; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-07-01       Impact factor: 9.097

10.  De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study.

Authors:  Djamel Mokart; Géraldine Slehofer; Jérôme Lambert; Antoine Sannini; Laurent Chow-Chine; Jean-Paul Brun; Pierre Berger; Ségolène Duran; Marion Faucher; Jean-Louis Blache; Colombe Saillard; Norbert Vey; Marc Leone
Journal:  Intensive Care Med       Date:  2014-01       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.